Sven M. Henrichwark
Sven, who joined Ampersand as an Operating Partner in 2022, serves as CEO of Fibronostics, an AI driven in vitro diagnostics company focused on the NASH/NAFLD market. He has over 20 years of operational leadership experience in the biotech, life science and medical technology industries. Prior to joining Ampersand, Sven was the EVP APAC of Avantor, CEO of Echosens, Global Commercial GM of GE Life Sciences Bioprocess, Service GM and COO of GE Healthcare in Asia Pacific and the CMO of GE Life Sciences. Sven holds a B.S. in Biology and a M.S. in Microbiology from the University of Duesseldorf.